BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 22027725)

  • 1. Paclitaxel and sirolimus differentially affect growth and motility of endothelial progenitor cells and coronary artery smooth muscle cells.
    Clever YP; Cremers B; Krauss B; Böhm M; Speck U; Laufs U; Scheller B
    EuroIntervention; 2011 May; 7 Suppl K():K32-42. PubMed ID: 22027725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative characterization of cellular and molecular anti-restenotic profiles of paclitaxel and sirolimus. Implications for local drug delivery.
    Wessely R; Blaich B; Belaiba RS; Merl S; Görlach A; Kastrati A; Schömig A
    Thromb Haemost; 2007 Jun; 97(6):1003-12. PubMed ID: 17549304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Local drug delivery - the early Berlin experience: single drug administration versus sustained release.
    Speck U; Scheller B; Rutsch W; Laule M; Stangl V
    EuroIntervention; 2011 May; 7 Suppl K():K17-22. PubMed ID: 22027723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative assessment of transient exposure of paclitaxel or zotarolimus on in vitro vascular cell death, proliferation, migration, and proinflammatory biomarker expression.
    Steinfeld DS; Liu AP; Hsu SH; Chan YF; Stankus JJ; Pacetti SD; Tai JT
    J Cardiovasc Pharmacol; 2012 Aug; 60(2):179-86. PubMed ID: 22561362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective randomised study using optical coherence tomography to assess endothelial coverage and neointimal proliferation at 6-months after implantation of a coronary everolimus-eluting stent compared with a bare metal stent postdilated with a paclitaxel-eluting balloon (OCTOPUS Trial): rationale, design and methods.
    Poerner TC; Otto S; Gassdorf J; Janiak F; Danzer C; Ferrari M; Figulla HR
    EuroIntervention; 2011 May; 7 Suppl K():K93-9. PubMed ID: 22027737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-eluting stents: sirolimus and paclitaxel differentially affect cultured cells and injured arteries.
    Parry TJ; Brosius R; Thyagarajan R; Carter D; Argentieri D; Falotico R; Siekierka J
    Eur J Pharmacol; 2005 Nov; 524(1-3):19-29. PubMed ID: 16271360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular effects of paclitaxel following drug-eluting balloon angioplasty in a porcine coronary model: the importance of excipients.
    Radke PW; Joner M; Joost A; Byrne RA; Hartwig S; Bayer G; Steigerwald K; Wittchow E
    EuroIntervention; 2011 Oct; 7(6):730-7. PubMed ID: 21986331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valproic acid inhibits proliferation of human coronary vascular cells (SI/MPL-ratio: 0.5): a novel candidate for systemic and local therapy of postinterventional restenosis.
    Voisard R; Krebs R; Baur R; Hombach V
    Coron Artery Dis; 2010 Aug; 21(5):286-91. PubMed ID: 20508518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutting balloon combined with paclitaxel-eluting balloon for treatment of in-stent restenosis.
    Kong J; Hou J; Ma L; Xing L; Jia H; Liu H; Zhang S; Yu B; Jang IK
    Arch Cardiovasc Dis; 2013 Feb; 106(2):79-85. PubMed ID: 23527911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiproliferative agents alter vascular plasminogen activator inhibitor-1 expression: a potential prothrombotic mechanism of drug-eluting stents.
    Muldowney JA; Stringham JR; Levy SE; Gleaves LA; Eren M; Piana RN; Vaughan DE
    Arterioscler Thromb Vasc Biol; 2007 Feb; 27(2):400-6. PubMed ID: 17158352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative vascular responses three months after paclitaxel and everolimus-eluting stent implantation in streptozotocin-induced diabetic porcine coronary arteries.
    Sheehy A; Hsu S; Bouchard A; Lema P; Savard C; Guy LG; Tai J; Polyakov I
    Cardiovasc Diabetol; 2012 Jun; 11():75. PubMed ID: 22716997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Local cyclin-dependent kinase inhibition by flavopiridol inhibits coronary artery smooth muscle cell proliferation and migration: Implications for the applicability on drug-eluting stents to prevent neointima formation following vascular injury.
    Jaschke B; Milz S; Vogeser M; Michaelis C; Vorpahl M; Schömig A; Kastrati A; Wessely R
    FASEB J; 2004 Aug; 18(11):1285-7. PubMed ID: 15180955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative healing response after sirolimus- and paclitaxel-eluting stent implantation in a pig model of restenosis.
    Silva GV; Fernandes MR; Madonna R; Clubb F; Oliveira E; Jimenez-Quevedo P; Branco R; Lopez J; Angeli FS; Sanz-Ruiz R; Vaughn WK; Zheng Y; Baimbridge F; Canales J; Cardoso CO; Assad JA; Falotico R; Perin EC
    Catheter Cardiovasc Interv; 2009 May; 73(6):801-8. PubMed ID: 19309735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-eluting stents.
    García-García HM; Vaina S; Tsuchida K; Serruys PW
    Arch Cardiol Mex; 2006; 76(3):297-319. PubMed ID: 17091802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From bench to Paccocath.
    Cremers B; Scheller B
    EuroIntervention; 2011 May; 7 Suppl K():K23-31. PubMed ID: 22027724
    [No Abstract]   [Full Text] [Related]  

  • 16. A perlecan-inducing compound significantly inhibits smooth muscle cell function and in-stent intimal hyperplasia: novel insights into the diverse biological effects of perlecan.
    Segev A; Nili N; Osherov AB; Qiang B; Wong AJ; Pillarisetti S; Strauss BH
    EuroIntervention; 2010 May; 6(1):134-40. PubMed ID: 20542809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale and design of the randomized, multicenter EREMUS trial, a study that investigates how to achieve low restenosis and early reendothelialization after percutaneous coronary interventions.
    Cortese B; Danzi GB; Pitì A; Severi S; Limbruno U
    Catheter Cardiovasc Interv; 2011 Jul; 78(1):32-7. PubMed ID: 21413116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two-year follow-up of the Genous™ endothelial progenitor cell capturing stent versus the Taxus Liberté stent in patients with de novo coronary artery lesions with a high-risk of restenosis: a randomized, single-center, pilot study.
    Beijk MA; Klomp M; van Geloven N; Koch KT; Henriques JP; Baan J; Vis MM; Tijssen JG; Piek JJ; de Winter RJ
    Catheter Cardiovasc Interv; 2011 Aug; 78(2):189-95. PubMed ID: 21542109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelial function rather than endothelial restoration is altered in paclitaxel- as compared to bare metal-, sirolimusand tacrolimus-eluting stents.
    van Beusekom HM; Sorop O; van den Heuvel M; Onuma Y; Duncker DJ; Danser AH; van der Giessen WJ
    EuroIntervention; 2010 May; 6(1):117-25. PubMed ID: 20542807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival of endothelial cells in vitro on Paclitaxel-loaded coronary stents.
    Prasad CK; Resmi KR; Krishnan LK; Vaishnav R
    J Biomater Appl; 2005 Apr; 19(4):271-86. PubMed ID: 15788425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.